Testing a new drug combo before surgery for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your liver cancer must have grown into the main blood vessels but not spread to other parts of the body.
- You cannot have had any prior cancer treatment, and your doctor believes the tumor might be removable with surgery.
- Your liver function must be good enough (Child-Pugh score A or B).
- You must have a tumor that can be measured on a scan.
- You must be willing to use effective birth control during and for a few months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining an immunotherapy drug (sintilimab) with targeted radiation therapy before surgery to shrink liver tumors and improve the chances of successful removal. It is designed for people with resectable liver cancer who have not yet had systemic treatment.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests giving a liver-directed chemotherapy (HAIC) plus an immunotherapy (PD-1) before surgery, followed by more immunotherapy after surgery, for people with a specific type of liver cancer that has a high chance of coming back. The goal is to see if this approach can reduce the risk of recurrence.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.